Management of women with systemic lupus erythematosus

Maturitas

Volumn 75, Issue 3, 2013, Pages 207-214

  Chugh, Preeta Kaur ^a  

^a SAFDARJUNG HOSPITAL   (India)

Author keywords

Cardiovascular risk; Lupus; Osteoporosis; Ovarian failure; SLE; Women

Indexed keywords

ALENDRONIC ACID; AMFEBUTAMONE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; DENOSUMAB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FONDAPARINUX; GONADORELIN AGONIST; HEPARIN; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW MOLECULAR WEIGHT HEPARIN; NICOTINE PATCH; ODANACATIB; ORAL ANTIDIABETIC AGENT; RISEDRONIC ACID; ROMOSOZUMAB; SCLEROSTIN; THIAZIDE DIURETIC AGENT; VARENICLINE; VITAMIN D; WARFARIN; ZOLEDRONIC ACID;

ANGINA PECTORIS; ANTICOAGULANT THERAPY; ATHEROSCLEROSIS; CAROTID ATHEROSCLEROSIS; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; CORONARY ARTERY CALCIFICATION; CRYOPRESERVATION; DIABETES MELLITUS; DYSLIPOPROTEINEMIA; ENDOTHELIAL DYSFUNCTION; FAMILY HISTORY; FERTILIZATION IN VITRO; FRAGILITY FRACTURE; FRAMINGHAM RISK SCORE; HEART FAILURE; HEART INFARCTION; HORMONAL THERAPY; HUMAN; HYPERGLYCEMIA; HYPERHOMOCYSTEINEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; LUNG EMBOLISM; MICROALBUMINURIA; NICOTINE REPLACEMENT THERAPY; OBESITY; OSTEOPENIA; OSTEOPOROSIS; PREMATURE OVARIAN FAILURE; REVIEW; SMOKING; SMOKING CESSATION; SUDDEN CARDIAC DEATH; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; THROMBOSIS PREVENTION; TOBACCO DEPENDENCE; VENOUS THROMBOEMBOLISM; WEIGHT REDUCTION;

CARDIOVASCULAR DISEASES; FEMALE; HUMANS; INFLAMMATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; MENOPAUSE, PREMATURE; NEOPLASMS; OSTEOPOROSIS; SURVIVORS;

EID: 84878534927     PISSN: 03785122     EISSN: 18734111     Source Type: Journal    
DOI: 10.1016/j.maturitas.2013.03.019     Document Type: Review

References (75)

1. P.K. Chugh Lupus: Novel therapies in clinical development European Journal of Internal Medicine 23 2012 212 218
2. Y. Ioannou, and D.A. Isenberg Current concepts for the management of systemic lupus erythematosus in adults: a therapeutic challenge Postgraduate Medical Journal 78 2002 599 606
3. C.E. Weckerle, and T.B. Niewold The unexplained female predominance of systemic lupus erythematosus: clues from genetic and cytokine studies Clinical Reviews in Allergy and Immunology 40 2011 42 49
4. S. Manzi, E.N. Meilahn, and J.E. Rairie Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study American Journal of Epidemiology 145 1997 408 415
5. I.N. Bruce, D.D. Gladman, and M.B. Urowitz Premature atherosclerosis in systemic lupus erythematosus Rheumatic Diseases Clinics of North America 26 2000 257 278
6. M.M. Ward Premature morbidity from cardiovascular and cerebrovasculardiseases in women with systemic lupus erythematosus Arthritis and Rheumatism 42 1999 338 346
7. C.C. Mok, S.S. Tang, C.H. To, and M. Petri Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups Arthritis and Rheumatism 52 2005 2774 2782
8. Z.S. Sarabi, E. Chang, and R. Bobba Incidence rates of arterial and venous thrombosis after diagnosis of systemic lupus erythematosus Arthritis and Rheumatism 53 2005 609 612
9. S. Manzi, F. Selzer, and K. Sutton-Tyrrell Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus Arthritis and Rheumatism 42 1999 51 60
10. J.M. Esdaile, M. Abrahamowicz, and T. Grodzicky Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus Arthritis and Rheumatism 44 2001 2331 2337
11. M. Petri Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort Lupus 9 2000 170 175
12. M. Petri, D. Spence, L.R. Bone, and M.C. Hochberg Coronary artery disease risk factors in the Johns Hopkins Lupus cohort: prevalence, recognition by patients and preventive practices Medicine 71 1992 291 302
13. R. Bessant, A. Hingorani, L. Patel, A. MacGregor, D.A. Isenberg, and A. Rahman Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus Rheumatology (Oxford) 43 2004 924 929
14. M. Petri, S. Perez-Gutthann, D. Spence, and M.C. Hochberg Risk factors for coronary artery disease in patients with systemic lupus erythematosus American Journal of Medicine 93 1992 513 519
15. C.C. Mok Accelerated atherosclerosis, arterial thromboembolism, and preventive strategies in systemic lupus erythematosus Scandinavian Journal of Rheumatology 35 2006 85 95
16. A.A. Long, J.S. Ginsberg, and P. Brill-Edwards The relationship of antiphospholipid antibodies to thromboembolic disease in systemic lupus erythematosus: a cross-sectional study Thrombosis and Haemostasis 66 1991 520 524
17. K. Manger, B. Manger, and R. Repp Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus Annals of the Rheumatic Diseases 61 2002 1065 1070
18. J.T. Willerson, and P.M. Ridker Inflammation as a cardiovascular risk factor Circulation 109 Suppl. 1 2004 II2 II10
19. P.W. Wilson, R.B. D'Agostino, D. Levy, A.M. Belanger, H. Silbershatz, and W.B. Kannel Prediction of coronary heart disease using risk factor categories Circulation 97 1998 1837 1847
20. R.M. Conroy, K. Pyörälä, and A.P. Fitzgerald Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project European Heart Journal 24 2003 987 1003
21. J. Wajed, Y. Ahmad, P.N. Durrington, and I.N. Bruce Prevention of cardiovascular disease in systemic lupus erythematosus - proposed guidelines for risk factor management Rheumatology (Oxford) 43 2004 7 12
22. T.A. Lakka, and J.T. Salonen Moderate to high intensity conditioning leisure time physical activity and high cardiorespiratory fitness are associated with reduced plasma fibrinogen in eastern Finnish men Journal of Clinical Epidemiology 46 1993 1119 1127
23. E.R. Eichner Exercise and arthritis. The hematology of inactivity Rheumatic Diseases Clinics of North America 16 1990 815 825
24. I. Graham, D. Atar, and K. Borch-Johnsen European guidelines on cardiovascular disease prevention in clinical practice: executive summary Atherosclerosis 194 2007 1 45
25. P.K. Chugh, and S. Sharma Recent advances in the pathophysiology and pharmacological treatment of obesity Journal of Clinical Pharmacy and Therapeutics 37 2012 525 535
26. N.O. Ghaussy, W. Sibbitt Jr., A.D. Bankhurst, and C.R. Qualls Cigarette smoking and disease activity in systemic lupus erythematosus Journal of Rheumatology 30 2003 1215 1221
27. E.F. Borba, and E. Bonfa Dyslipoproteinemias in systemic lupus erythematosus: influence of disease activity and anticardiolipin antibodies Lupus 6 1997 533 539
28. C. Skamra, and R. Ramsey-Goldman Management of cardiovascular complications in systemic lupus erythematosus International Journal of Clinical Rheumatology 5 2010 75 100
29. Expert Panel on Detection Evaluation and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Programme (NCEP) expert panel in detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III) Journal of the American Medical Association 285 2001 2486 2497
30. C. Baigent, A. Keech, and P.M. Kearney Cholesterol Treatment Trialists' (CTT) collaborators. Efficacy and safety of cholesterol lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278
31. B. Neal, S. Macmahon, and N. Chapman Effects of ace inhibitors, calcium antagonists, and other blood pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood pressure lowering treatment trialists' collaboration Lancet 356 2000 1955 1964
32. A.V. Chobanian, G.L. Bakris, and H.R. Black The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report Journal of the American Medical Association 289 2003 2560 2572
33. L.E. Ramsay, B. Williams, and G.D. Johnston Guidelines for the management of hypertension: report of the third working party of the British Hypertension Society Journal of Human Hypertension 13 1999 569 592
34. S. Duran-Barragan, G. Mcgwin Jr., L.M. Vila, J.D. Reveille, and G.S. Alarcon Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus - results from LUMINA (LIX): a multiethnic US cohort Rheumatology 47 2008 1093 1096
35. J.D. Coffman Raynaud's phenomenon an update Hypertension 17 1991 593 602
36. G. Ruiz-Irastorza, M.V. Egurbide, and J.I. Pijoan Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus Lupus 15 2006 577 583
37. M.A. Crowther, J.S. Ginsberg, and J. Julian A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome New England Journal of Medicine 349 2003 1133 1138
38. G. Finazzi, R. Marchioli, and V. Brancaccio A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS) Journal of Thrombosis and Haemostasis 3 2005 848 853
39. G. Ruiz-Irastorza, B.J. Hunt, and M.A. Khamashta A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies Arthritis and Rheumatism 57 2007 1487 1495
40. R.S. Kasthuri, and R.A. Roubey Warfarin and the antiphospholipid syndrome: does one size fit all? Arthritis and Rheumatism 57 2007 1346 1347
41. D. Erkan, M.J. Harrison, and R. Levy Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized,double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals Arthritis and Rheumatism 56 2007 2382 2391
42. S.R. Kahn, W. Lim, A.S. Dunn, M. Cushman, F. Dentali, and E.A. Akl American College of Chest Physicians. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 Suppl. 2 2012 e195S e226S
43. I.E. Bultink, M. Vis, I.E. van der Horst-Bruinsma, and W.F. Lems Inflammatory rheumatic disorders and bone Current Rheumatology Reports 14 2012 224 230
44. A.A. Kalla, A.B. Fataar, S.J. Jessop, and L. Bewerunge Loss of trabecular bone mineral density in systemic lupus erythematosus Arthritis and Rheumatism 36 1993 1726 1734
45. C.C. Mok, A. Mak, and K.M. Ma Bone mineral density in postmenopausal Chinese patients with systemic lupus erythematosus Lupus 14 2005 106 112
46. M. Boyanov, R. Robeva, and P. Popivanov Bone mineral density changes in women with systemic lupus erythematosus Clinical Rheumatology 22 2003 318 323
47. S. Uaratanawong, U. Deesomchoke, S. Lertmaharit, and S. Uaratanawong Bone mineral density in premenopausal women with systemic lupus erythematosus Journal of Rheumatology 30 2003 2365 2368
48. I.E. Bultink Osteoporosis and fractures in systemic lupus erythematosus Arthritis Care Research (Hoboken) 64 2012 2 8
49. S. Lakshminarayanan, S. Walsh, M. Mohanraj, and N. Rothfield Factors associated with low bone mineral density in patients with systemic lupus erythematosus Journal of Rheumatology 28 2001 102 108
50. J.M. Grossman, R. Gordon, and V.K. Ranganath American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis Arthritis Care Research (Hoboken) 62 2010 1515 1526
51. E. Shane, D. Burr, and P.R. Ebeling Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research Journal of Bone and Mineral Research 25 2010 2267 2294
52. J. Sanchez-Guerrero, H.E. Fragoso-Loyo, and C.M. Neuwelt Effects of prasterone on bone mineral density in women with active systemic lupus erythematosus receiving chronic glucocorticoid therapy Journal of Rheumatology 35 2008 1567 1575
53. W. Marder, E.C. Somers, M.J. Kaplan, M.R. Anderson, E.E. Lewis, and W.J. McCune Effects of prasterone (dehydroepiandrosterone) on markers of cardiovascular risk and bone turnover in premenopausal women with systemic lupus erythematosus: a pilot study Lupus 19 2010 1229 1236
54. C.C. Mok, C.H. To, A. Mak, and K.M. Ma Raloxifene for postmenopausal women with systemic lupus erythematosus: a pilot randomized controlled study Arthritis and Rheumatism 52 2005 3997 4002
55. L. Silva-Fernández, M.P. Rosario, J.A. Martínez- López, L. Carmona, and E. Loza Denosumab for the treatment of osteoporosis: a systematic literature review Reumatología Clínica 9 2013 42 52
56. S. Papapoulos, R. Chapurlat, and C. Libanati Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension Journal of Bone and Mineral Research 27 2012 694 701
57. E.M. Lewiecki New targets for intervention in the treatment of postmenopausal osteoporosis Nature Reviews Rheumatology 7 2011 631 638
58. L.M. Nelson Clinical practice. Primary ovarian insufficiency New England Journal of Medicine 360 2009 606 614
59. A.M. Bertoli, and G.S. Alarcon Epidemiology of systemic lupus erythematosus G.C. Tsokos, C. Gordon, J.S. Smolen, Systemic lupus erythematosus: a companion to rheumatology 2007 Mosby Elsevier Philadelphia 1 18
60. C.C. Mok, C.S. Lau, and R.W. Wong Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy Arthritis and Rheumatism 41 1998 831 837
61. M.M. Medeiros, V.A. Silveira, A.P. Menezes, and R.C. Carvalho Risk factors for ovarian failure in patients with systemic lupus erythematosus Brazilian Journal of Medical and Biological Research 34 2001 1561 1568
62. F. Atsma, M.L. Bartelink, D.E. Grobbee, and Y.T. van der Schouw Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis Menopause 13 2006 265 279
63. J.C. Gallagher Effect of early menopause on bone mineral density and fractures Menopause 14 2007 567 571
64. B.K. Jacobsen, S.F. Knutsen, and G.E. Fraser Age at natural menopause and total mortality and mortality from ischemic heart disease: the Adventist Health Study Journal of Clinical Epidemiology 52 1999 303 307
65. J.G. van der Stege, H. Groen, and S.J. van Zadelhoff Decreased androgen concentrations and diminished general and sexual well-being in women with premature ovarian failure Menopause 15 2008 23 31
66. Z. Blumenfeld, D. Shapiro, M. Shteinberg, I. Avivi, and M. Nahir Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy Lupus 9 2000 401 405
67. Z. Blumenfeld How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries Oncologist 12 2007 1044 1054
68. M. Huser, J. Zakova, and L. Smardova Combination of fertility preservation strategies in young women with recently diagnosed cancer European Journal of Gynaecological Oncology 33 2012 42 50
69. E.C. Somers, W. Marder, G.M. Christman, V. Ognenovski, and W.J. McCune Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus Arthritis and Rheumatism 52 2005 2761 2767
70. Z. Blumenfeld Gynaecologic concerns for young women exposed to gonadotoxic chemotherapy Current Opinion in Obstetrics and Gynecology 15 2003 359 370
71. J. Bellver, and A. Pellicer Ovarian stimulation for ovulation induction and in vitro fertilization in patients with systemic lupus erythematosus and antiphospholipid syndrome Fertility and Sterility 92 2009 1803 1810
72. A. Lateef, and M. Petri Hormone replacement and contraceptive therapy in autoimmune diseases Journal of Autoimmunity 38 2012 J170 J176
73. M. Petri, M.Y. Kim, and K.C. Kalunian Combined oral contraceptives in women with systemic lupus erythematosus New England Journal of Medicine 353 2005 2550 2558
74. J. Sanchez-Guerrero, A.G. Uribe, and L. Jimenez-Santana A trial of contraceptive methods in women with systemic lupus erythematosus New England Journal of Medicine 353 2005 2539 2549
75. F. Tremollieres, M. Brincat, and C.T. Erel European Menopause and Andropause Society. EMAS position statement: managing menopausal women with a personal or family history of VTE Maturitas 69 2011 195 198